» Articles » PMID: 9223843

Strychnine-like Multifocal Myoclonus and Seizures in Extremely High-dose Opioid Administration: Treatment Strategies

Overview
Publisher Elsevier
Date 1997 Jul 1
PMID 9223843
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

While occasional myoclonic jerks are prevalent in cancer patients receiving opioids, severe myoclonic jerks and seizures due to opioids are uncommon. In this retrospective case series, we describe five cancer patients with refractory cancer pain and severe neuroexcitatory toxicity associated with extremely high-dose opioid therapy to characterize better the syndrome, its treatment, and its outcome. Two patients died following seizures, but three patients recovered following prompt treatment with parenteral midazolam infusions and rotation to alternative opioids. Possible mechanisms and treatment options for this potentially lethal clinical syndrome are reviewed. The authors conclude that severe multifocal myoclonus and seizures associated with extremely high-dose opioid therapy are life-threatening, and respond to parenteral midazolam infusion, rotation to alternative opioids, and aggressive supportive care.

Citing Articles

Development of an Effective Monoclonal Antibody against Heroin and Its Metabolites Reveals Therapies Have Mistargeted 6-Monoacetylmorphine and Morphine over Heroin.

Lee J, Eubanks L, Zhou B, Janda K ACS Cent Sci. 2022; 8(10):1464-1470.

PMID: 36313156 PMC: 9615117. DOI: 10.1021/acscentsci.2c00977.


Morphine-3-Glucuronide, Physiology and Behavior.

Gabel F, Hovhannisyan V, Berkati A, Goumon Y Front Mol Neurosci. 2022; 15:882443.

PMID: 35645730 PMC: 9134088. DOI: 10.3389/fnmol.2022.882443.


Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine.

Woodward O, Naraen S, Naraen A Br J Pain. 2017; 11(1):32-35.

PMID: 28386402 PMC: 5370622. DOI: 10.1177/2049463716664371.


Drug-associated delirium in cancer patients.

Caraceni A EJC Suppl. 2015; 11(2):233-40.

PMID: 26217132 PMC: 4041541. DOI: 10.1016/j.ejcsup.2013.07.008.


OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Carter N, Keating G CNS Drugs. 2010; 24(4):337-61.

PMID: 20297858 DOI: 10.2165/11202580-000000000-00000.